Plain-English translation of NCT05969171 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether surufatinib, a new medication, works better when combined with standard chemotherapy drugs (gemcitabine and nab-paclitaxel) to treat advanced pancreatic cancer. You would be eligible if your cancer has already been treated with two rounds of this chemotherapy combination without getting worse. Half of participants will receive the new medication plus the chemotherapy, while the other half will receive the chemotherapy alone.
Pancreatic cancer is very difficult to treat, and patients need better options. Researchers believe that adding this new medication to the standard chemotherapy regimen may help slow cancer growth and improve survival for people whose cancer has not progressed after initial treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one receiving the new medication by mouth daily plus chemotherapy infusions, or the other receiving chemotherapy alone. The chemotherapy is given intravenously on days 1 and 8 of each 3-week cycle, up to a maximum of 6 cycles. You will have imaging scans every 6 weeks to check how your cancer is responding, and regular blood tests to monitor your health and side effects. Treatment continues until your cancer progresses, side effects become intolerable, or you reach the maximum number of cycles.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China